MK-2225

Phase 1Small molecule

Merck & Co.

MK-2225 is one of 47 small molecule programs targeting Interstitial Lung Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Interstitial Lung DiseaseActive, not recruiting

Interstitial Lung DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

85 competitors in Interstitial Lung Disease

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

4 2

Cellcept

Roche

Phase 3

4 3

Actemra

Roche

Phase 3

1 4

Cialis

Eli Lilly

Phase 3

1 5

Prograf

VVeloxis Pharmaceuticals

Phase 3

1 6

Jascayd

Boehringer Ingelheim

Phase 3

1 7

Benlysta

GGlaxo Dba Glaxosmithkline

Phase 3

1 8

Orencia

Bristol-Myers Squibb

Phase 2

2 9

Elavil

AstraZeneca

Phase 2

1 10

Cymbalta

Alnylam Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

ART1 trial

A Study of MK-2225 in Healthy Participants (MK-2225-003)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT06643390·32 enrolled

Interstitial Lung Disease1 trial

A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT04948554·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for MK-2225. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MK-2225 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MK-2225. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Merck & Co.

MK-2225

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

ART1 trial

Interstitial Lung Disease1 trial

References

Drug Info

Quick Facts

Related News